We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biochemical Changes in Stored Donor Units Analyzed

By LabMedica International staff writers
Posted on 12 Jul 2018
Print article
Image: The HumaStar 80 clinical chemistry analyzer (Photo courtesy of Human Diagnostics).
Image: The HumaStar 80 clinical chemistry analyzer (Photo courtesy of Human Diagnostics).
Blood transfusion with allogeneic blood products is a common medical intervention to treat anemia or prepare patients for surgical procedures and generally, the blood units are secured and stored prior to expected transfusion.

During storage, several physical and biochemical changes take place in blood products that await transfusion, and the most affected product is whole blood. These changes known collectively as red cell storage lesion are progressive events that affect blood products stored for longer period than products stored for a short period.

Medical Laboratory Scientists at Mbarara University of Science and Technology (Mbarara, Uganda) recruited consecutively a total of 200 blood recipients were categorized into two study arms: group I of 100 received fresh blood and 100 in group II received old blood. A total of 2 mL of venous blood was collected from each participant in EDTA tubes before transfusion for pre-transfusion hemoglobin (Hb) estimation and after transfusion for post-transfusion Hb estimation. Each cross-matched unit was sampled to collect plasma for pH, lactate and potassium assays.

The Hb level was estimated using a Beckman Coulter Diagnostics full hemogram machine; donor lactate level was determined using HumaStar 80; and the potassium and pH in the donor units were determined by Human Diagnostics’ HumaLyte assays. Donor units were cultured in blood agar medium and incubated for 24 hours at 37 °C.

The team reported that the pH of the stored blood dropped from 7.4 to 7.2 in the first three days to ~7.0 by day 11 and to <7.0 by day 35. The mean rise in lactate level was 25 g/dL in blood stored for 0 to 11 days and 32.4 g/dL in blood stored for 21 to 35 days. The highest increase was encountered in blood stored beyond 28 days: 40–57 g/dL by 35 days. Potassium levels equally increased from ~4.6 mmol/L in the first five days of storage to ~14.3 mmol/L by 11 days. From the third week of blood storage and beyond, there was exponential increase in potassium levels, with the highest record in blood units stored from 30 to 35 days.

The authors concluded that whole blood stored for more than 14 days has reduced efficacy with increased markers of red cell storage lesion such as increased potassium level, lactate and fall in pH and these lesions increase the length of hospital stay. The study was published on June 25, 2018, in the Journal of Blood Medicine.

Related Links:
Mbarara University of Science and Technology

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.